The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Metsera expects its cash will last into 2027. Two other life science companies went public this past week. Here’s a look at those IPOs: Maze Therapeutics Finds Way to $140M IPO for Chronic ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Cystic fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

Metsera raised $275 million in its IPO ... Also on Thursday, Maze Therapeutics priced an upsized IPO at $16 a share, in the middle of a marketed range, according to a statement.

Recent health news includes significant developments such as Akero Therapeutics' promising liver disease drug, potential ...

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and $140 million, respectively, in a pair of new stock offerings priced ...